Tevogen Inc. (TVGNW)
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company focused on developing ready-to-use, precision T cell therapies. Their research and development efforts span virology, oncology, and neurological conditions. The company's flagship experimental treatment, TVGN 489, is a precision T cell product designed to meet the unmet needs of individuals severely affected by acute COVID-19, as well as a specific group of patients struggling with long COVID. Tevogen Bio Holdings Inc. is headquartered in Warren, New Jersey.
Sector: Biological Products, (No Diagnostic Substances)
Tevogen Inc.
NASDAQ:TVGNWSub-class of TVGN
-2.64%$0.0847
CLOSED · Nov 6Prev close$0.0870-2.64%Close$0.0847+3.90%AH close$0.0880
AH$0.0880+3.90%vs close
Mkt Cap$5.75M
Float43.58M
O/S67.88M
VOL759K sh
$ Vol$62K
RVOL1.50×
Inst Own-
SI0.2%
EarningsNov 13 · in 4d
Dilution
Financials Summary
Revenue$0
Net Income-$26.28M
Total Assets$4.38M
Free Cash Flow-$12.39M
Debt & Equity
Debt 85%
Preferred 240%
Total Debt$3.1M
Total Equity-$8.23M
Preferred Stock$8.8M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in TVGNW's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$4.38M
Liabilities$12.62M
Accounts Receivable$159K
Accounts Payable$3.34M
Inventory$0
PP&E (Net)$1.59M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - |
| Cost of Revenue | $0 | $404K | $378K | $0 | $0 |
| Gross Profit | $0 | -$404K | -$378K | $0 | $0 |
| Gross Margin | - | - | - | - | - |
| Research and Development | $11.11M | $31.03M | $4.4M | $0 | $2.96M |
| Selling, General, and Administrative | $15.03M | $22.13M | $4.06M | $953K | $1.66M |
| Other | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $26.14M | $53.16M | $8.46M | $953K | $4.62M |
| Operating Income (EBIT) | -$26.14M | -$53.56M | -$8.84M | -$953K | -$4.62M |
| Operating Margin | - | - | - | - | - |
| Interest Expense | $196K | $184K | $256K | $0 | $599K |
| Interest Income | $0 | $0 | $0 | $4.95M | $0 |
| Other Income (Expense) | -$135K | $39.84M | -$51.63M | $5.36M | -$10.98M |
| Income Before Tax (EBT) | -$26.28M | -$13.73M | -$60.48M | $4.41M | -$15.6M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$26.28M | -$10.11M | -$60.48M | $4.41M | -$15.6M |
| Net Income Margin | - | - | - | - | - |
| Supplementary Data | |||||
| EPS | -8.08 | -4.68 | -0.02 | 1.83 | -16.50 |
| Diluted EPS | -8.08 | -4.68 | -0.02 | 1.83 | -16.50 |
| Weighted Average OS | 3.32M | 2.93M | 3.31M | 2.40M | 958,667 |
| EBITDA | -$25.57M | -$13.14M | -$58.89M | $4.64M | -$14.99M |
| EBITDA Margin | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $552K | $1.28M | $1.05M | $5.48M | $7.12M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $552K | $1.28M | $1.05M | $5.48M | $7.12M |
| Accounts Receivable | $159K | $159K | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $829K | $919K | $0 | $0 | $54K |
| Total Current Assets | $1.54M | $2.36M | $1.72M | $5.84M | $7.17M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $1.59M | $525K | $929K | $1.31M | $143K |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $351.92M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.25M | $576K | $2.85M | $595K | -$351.57M |
| Total Long-Term Assets | $2.84M | $1.1M | $3.78M | $1.9M | $485K |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $4.38M | $3.46M | $5.51M | $7.74M | $7.66M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $3.34M | $5.2M | $3.42M | $866K | $378K |
| Short-Term Debt | $1.98M | $1.65M | $80.71M | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.5M | $403K | $120K | $238K | $45K |
| Total Current Liabilities | $7.07M | $9.04M | $85.48M | $1.96M | $668K |
| Long-Term Liabilities | |||||
| Long-Term Debt | $1.12M | $1M | $14.22M | $39.3M | $23.48M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $4.43M | $87K | $0 | $0 | $0 |
| Total Long-Term Liabilities | $5.55M | $1.09M | $14.45M | $39.73M | $23.48M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $12.62M | $10.14M | $99.93M | $41.69M | $24.15M |
| Stockholders' Equity | |||||
| Preferred Stock | $8.8M | $8.8M | $0 | $0 | $0 |
| Common Stock | $402 | $18K | $12K | $62K | $64K |
| Retained Earnings | -$139.66M | -$113.39M | -$99.66M | -$39.18M | -$17.14M |
| Comprehensive Income & Other | $0 | $0 | -$0 | -$0 | $0 |
| Other Stockholders' Equity | $131.43M | $106.69M | $5.22M | $5.17M | $586K |
| Total Equity | -$8.23M | -$6.67M | -$94.43M | -$33.95M | -$16.49M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $4.38M | $3.46M | $5.51M | $7.74M | $7.66M |
| Supplementary Data | |||||
| Total Debt | $3.1M | $2.89M | $95.42M | $40.01M | $23.48M |
| Net Debt | $2.55M | $1.6M | $94.37M | $34.52M | $16.36M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$26.28M | -$13.73M | -$60.48M | -$22.04M | -$15.6M |
| Depreciation & Amortization | $509K | $404K | $378K | $231K | $9K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $16.22M | $40.76M | $0 | $4.58M | $582K |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | -$267K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.96M | $1.69M | $1.11M | $0 | -$1.09M |
| Other Working Capital | -$760K | -$1.69M | -$554K | -$97K | -$156K |
| Total Working Capital Change | -$2.72M | -$5K | $293K | -$97K | -$1.25M |
| Other Non-Cash Items | -$61K | -$39.43M | $51.63M | $8.67M | $10.98M |
| Net Cash from Operating | -$12.33M | -$12M | -$8.17M | -$8.66M | -$5.27M |
| Investing Activities | |||||
| Capital Expenditures | -$64K | $0 | -$133K | -$479K | -$110K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$64K | $0 | -$133K | -$479K | -$110K |
| Financing Activities | |||||
| Debt Repaid | -$3.4M | -$1M | -$4M | -$7.5M | -$12.5M |
| Common Stock Issuance | $4.86M | $0 | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | -$342.98M | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $3.4M | $229K | $342.86M | $0 | $0 |
| Net Cash from Financing | $11.66M | $12.23M | $3.87M | $7.5M | $12.5M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$731K | $231K | -$4.43M | -$1.63M | $7.12M |
| Supplementary Data | |||||
| Operating Cash Flow | -$12.33M | -$12M | -$8.17M | -$8.66M | -$5.27M |
| Capital Expenditure | -$64K | $0 | -$133K | -$479K | -$110K |
| Free Cash Flow | -$12.39M | -$12M | -$8.3M | -$9.13M | -$5.38M |
| Cash at Beginning | $1.28M | $1.05M | $5.48M | $7.12M | $4K |
| Cash at End | $552K | $1.28M | $1.05M | $5.48M | $7.12M |